Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | GRPR | P30550 | 3/20 | 0.34 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.33 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31713935 | 0.96 | BACE1 (0.38) | BACE1ELANEMMEECE1GRPR | |
| SCHEMBL78173 | 0.90 | ACE (0.36) | MMEECE1 | |
| SCHEMBL79320 | 0.90 | ACE (0.36) | MMEECE1 | |
| SCHEMBL78174 | 0.90 | ACE (0.36) | MMEECE1 | |
| SCHEMBL29630385 | 0.88 | BACE1 (0.39) | BACE1MMEECE1BMP1KMT2A | |
| SCHEMBL29794264 | 0.88 | BACE1 (0.44) | BACE1GRPRERAP2 | |
| SCHEMBL30129742 | 0.87 | ECE1 (0.43) | BACE1ELANEMMEECE1PRSS1 | |
| SCHEMBL30918507 | 0.87 | MAGI3 (0.37) | BACE1ELANEMMEECE1KMT2A | |
| SCHEMBL30658572 | 0.86 | ERAP2 (0.40) | BACE1MMEERAP2 | |
| SCHEMBL20397476 | 0.85 | FNTA (0.37) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | BACE1 2081/4885ELANE 1892/4885MME 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.